Bucher, HC

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 13.

Journal Article

Bucher, HC; Richter, W; Glass, TR; Magenta, L; Wang, Q; Cavassini, M; Vernazza, P; Hirschel, B; Weber, R; Furrer, H; Battegay, M; Bernasconi, E (2011). Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes JAIDS, 60(2), pp. 135-142. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e31824476e1

Sterne, JA; May, M; Bucher, HC; Ledergerber, B; Furrer, H; Cavassini, M; Bernasconi, E; Hirschel, B; Egger, M; Swiss, HIV Cohort (2007). HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Journal of internal medicine, 261(3), pp. 255-67. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2796.2006.01761.x

Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss, HIV Cohort Study (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8), pp. 1165-73. London: International Medical Press

Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1

Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press

Wolbers, M; Battegay, M; Hirschel, B; Furrer, H; Cavassini, M; Hasse, B; Vernazza, PL; Bernasconi, E; Kaufmann, G; Bucher, HC; Swiss, HIV Cohort Study (2007). CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy, 12(6), pp. 889-97. London: International Medical Press

Glass, TR; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2007). Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV clinical trials, 8(2), pp. 77-85. St. Louis, Mo.: Thomas Land Publishers 10.1310/hct0802-77

Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2006). Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine, 7(6), pp. 404-10. Oxford: Blackwell Science 10.1111/j.1468-1293.2006.00400.x

Briel, M; Boscacci, R; Furrer, H; Bucher, HC (2005). Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC infectious diseases, 5(5), p. 101. London: BioMed Central 10.1186/1471-2334-5-101

Wunder, D; Bersinger, NA; Fux, C; Weber, R; Bernasconi, E; Cavassini, M; Bucher, HC; Schiffer, V; Schmid, P; Furrer, H; Swiss, HIV Cohort Study (2005). Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS, 19(16), pp. 1837-42. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000189852.21441.2a

Young, J; Weber, R; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy, 10(5), pp. 585-91. London: International Medical Press

Rauch, A; Rickenbach, M; Weber, R; Hirschel, B; Tarr, PE; Bucher, HC; Vernazza, P; Bernasconi, E; Zinkernagel, AS; Evison, J; Furrer, H; Swiss, HIV Cohort Study (2005). Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases, 41(3), pp. 395-402. Cary, N.C.: The University of Chicago Press 10.1086/431486

Young, J; Rickenbach, M; Weber, R; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy, 10(1), pp. 73-81. London: International Medical Press

This list was generated on Mon Dec 30 07:57:59 2024 CET.
Provide Feedback